Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1972 1
1975 1
1976 1
1977 1
1978 4
1980 2
1981 3
1982 3
1983 5
1984 6
1985 4
1986 2
1987 3
1988 3
1989 6
1990 5
1991 8
1992 3
1993 9
1994 13
1995 10
1996 7
1997 8
1998 4
1999 9
2000 6
2001 7
2002 5
2003 9
2004 5
2005 8
2006 13
2007 9
2008 15
2009 21
2010 35
2011 35
2012 25
2013 27
2014 33
2015 32
2016 28
2017 38
2018 35
2019 30
2020 57
2021 52
2022 35
2023 42
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

659 results

Results by year

Filters applied: . Clear all
Page 1
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Goodwin GM, et al. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. N Engl J Med. 2022. PMID: 36322843 Clinical Trial.
Secondary end points included response at week 3 (50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score 10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits). ...In the 25-mg group, th …
Secondary end points included response at week 3 (50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total sco …
Chronic Kidney Disease-Associated Pruritus: A Review.
Makar M, Smyth B, Brennan F. Makar M, et al. Kidney Blood Press Res. 2021;46(6):659-669. doi: 10.1159/000518391. Epub 2021 Sep 7. Kidney Blood Press Res. 2021. PMID: 34515143 Free article. Review.
The exact pathogenesis remains largely elusive, which hampers the synthesis of a definite treatment approach. SUMMARY: Chronic pruritus (lasting 6 weeks or more in duration) is a common and potentially disabling symptom in patients with advanced CKD. ...
The exact pathogenesis remains largely elusive, which hampers the synthesis of a definite treatment approach. SUMMARY: Chronic pruritus (las …
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O'Malley JT, Porter-Brown B. Weidinger S, et al. Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240. Br J Dermatol. 2023. PMID: 37463508 Free article. Clinical Trial.
OBJECTIVES: To assess the safety and efficacy of amlitelimab over 16 weeks in adults with AD in a phase IIa double-blind placebo-controlled study. ...Numerically greater reductions in EASI were observed for amlitelimab vs. placebo from weeks 2 to 16. CONCLUSIONS: No …
OBJECTIVES: To assess the safety and efficacy of amlitelimab over 16 weeks in adults with AD in a phase IIa double-blind placebo-cont …
The impact of skin care products on skin chemistry and microbiome dynamics.
Bouslimani A, da Silva R, Kosciolek T, Janssen S, Callewaert C, Amir A, Dorrestein K, Melnik AV, Zaramela LS, Kim JN, Humphrey G, Schwartz T, Sanders K, Brennan C, Luzzatto-Knaan T, Ackermann G, McDonald D, Zengler K, Knight R, Dorrestein PC. Bouslimani A, et al. BMC Biol. 2019 Jun 12;17(1):47. doi: 10.1186/s12915-019-0660-6. BMC Biol. 2019. PMID: 31189482 Free PMC article.
We evaluated the impact of four beauty products (a facial lotion, a moisturizer, a foot powder, and a deodorant) on 11 volunteers over 9 weeks. RESULTS: Mass spectrometry and 16S rRNA inventories of the skin revealed decreases in chemical as well as in bacterial and archae …
We evaluated the impact of four beauty products (a facial lotion, a moisturizer, a foot powder, and a deodorant) on 11 volunteers over 9 …
Topical antibiotics for chronic suppurative otitis media.
Brennan-Jones CG, Head K, Chong LY, Burton MJ, Schilder AG, Bhutta MF. Brennan-Jones CG, et al. Cochrane Database Syst Rev. 2020 Jan 2;1(1):CD013051. doi: 10.1002/14651858.CD013051.pub2. Cochrane Database Syst Rev. 2020. PMID: 31896168 Free PMC article.
Our primary outcomes were: resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not), measured at between one week and up to two weeks, two weeks to up to four weeks and after four weeks; health-related quality of life using a v …
Our primary outcomes were: resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not), measured at between one week a …
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
Fakih M, Raghav KPS, Chang DZ, Larson T, Cohn AL, Huyck TK, Cosgrove D, Fiorillo JA, Tam R, D'Adamo D, Sharma N, Brennan BJ, Wang YA, Coppieters S, Zebger-Gong H, Weispfenning A, Seidel H, Ploeger BA, Mueller U, Oliveira CSV, Paulson AS. Fakih M, et al. EClinicalMedicine. 2023 Apr 6;58:101917. doi: 10.1016/j.eclinm.2023.101917. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 37090438 Free PMC article.
Eligible patients had known extended RAS and BRAF status, progression or intolerance to no more than two (for extended RAS mutant) or three (for extended RAS wild type) lines of systemic chemotherapy and an Eastern Cooperative Oncology Group performance status of 0 or 1. Regorafe …
Eligible patients had known extended RAS and BRAF status, progression or intolerance to no more than two (for extended RAS mutant) or three …
Exercise and manual physiotherapy arthritis research trial (EMPART) for osteoarthritis of the hip: a multicenter randomized controlled trial.
French HP, Cusack T, Brennan A, Caffrey A, Conroy R, Cuddy V, FitzGerald OM, Fitzpatrick M, Gilsenan C, Kane D, O'Connell PG, White B, McCarthy GM. French HP, et al. Arch Phys Med Rehabil. 2013 Feb;94(2):302-14. doi: 10.1016/j.apmr.2012.09.030. Epub 2012 Oct 16. Arch Phys Med Rehabil. 2013. PMID: 23084955 Free article. Clinical Trial.
INTERVENTIONS: Participants in both the ET and ET+MT groups received up to 8 treatments over 8 weeks. Control group participants were rerandomized into either ET or ET+MT groups after 9 week follow-up. ...RESULTS: There was no significant difference in WOMAC PF between the …
INTERVENTIONS: Participants in both the ET and ET+MT groups received up to 8 treatments over 8 weeks. Control group participants were …
Systemic antibiotics for chronic suppurative otitis media.
Chong LY, Head K, Webster KE, Dew J, Richmond P, Snelling T, Bhutta MF, Schilder AG, Burton MJ, Brennan-Jones CG. Chong LY, et al. Cochrane Database Syst Rev. 2021 Feb 4;2(2):CD013052. doi: 10.1002/14651858.CD013052.pub2. Cochrane Database Syst Rev. 2021. PMID: 35819801 Free PMC article. Review.
Our primary outcomes were: resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not, measured at between one week and up to two weeks, two weeks to up to four weeks, and after four weeks); health-related quality of life using a …
Our primary outcomes were: resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not, measured at between one week an …
Topical versus systemic antibiotics for chronic suppurative otitis media.
Chong LY, Head K, Webster KE, Daw J, Richmond P, Snelling T, Bhutta MF, Schilder AG, Burton MJ, Brennan-Jones CG. Chong LY, et al. Cochrane Database Syst Rev. 2021 Feb 9;2(2):CD013053. doi: 10.1002/14651858.CD013053.pub2. Cochrane Database Syst Rev. 2021. PMID: 33561891 Free PMC article.
Our primary outcomes were: resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not, measured at between one week and up to two weeks, two weeks up to four weeks, and after four weeks), health-related quality of life using a val …
Our primary outcomes were: resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not, measured at between one week an …
Pregnancy-associated changes in cervical noncoding RNA.
Gerson KD, Haviland MJ, Neo D, Hecht JL, Baccarelli AA, Brennan KJ, Dereix AE, Ralston SJ, Hacker MR, Burris HH. Gerson KD, et al. Epigenomics. 2020 Jun;12(12):1013-1025. doi: 10.2217/epi-2019-0231. Epub 2020 Aug 18. Epigenomics. 2020. PMID: 32808540 Free PMC article.
Materials & methods: We enrolled 21 pregnant women with term deliveries (37 weeks' gestation) in a prospective cohort and collected cervical swabs before 28 weeks' gestation. ...
Materials & methods: We enrolled 21 pregnant women with term deliveries (37 weeks' gestation) in a prospective cohort and collect …
659 results